G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit
G1 Therapeutics (Nasdaq: GTHX), a commercial-stage oncology company, announced that its Chief Medical Officer, Dr. Raj Malik, and Chief Commercial Officer, Andrew Perry, will participate in TD Cowen’s 5th Annual Oncology Innovation Summit.
The event will take place on May 29, 2024, at 8:30 AM EDT. A webcast of the fireside chat will be available on the company's Events & Presentations page.
- G1 Therapeutics' participation in a high-profile oncology summit can enhance visibility and investor confidence.
- Engagement with the oncology community and industry leaders may offer strategic opportunities for G1 Therapeutics.
- The press release does not mention any new product developments or financial updates, which may be perceived as a lack of progress.
- No concrete data or outcomes are associated with the summit participation, making it unclear how this will directly benefit shareholders.
RESEARCH TRIANGLE PARK, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Medical Officer Dr. Raj Malik and Chief Commercial Officer Andrew Perry will participate in a fireside chat at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on Wednesday, May 29, at 8:30AM EDT.
The webcast of the event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). The Company is also evaluating therapies in combination with cytotoxic therapies and/or immunotherapy in areas of high unmet need including triple-negative breast cancer and extensive stage small cell lung cancer. G1’s goal is to provide innovative therapeutic advances for people living with cancer. G1 is based in Research Triangle Park, N.C. For additional information, please visit http://www.g1therapeutics.com and follow us on X (formerly known as Twitter) @G1Therapeutics and LinkedIn.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc.
Contacts:
Will Roberts
Communications Officer
Vice President, Investor Relations and Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com
FAQ
When will G1 Therapeutics participate in the TD Cowen’s 5th Annual Oncology Innovation Summit?
Who will represent G1 Therapeutics at the Oncology Innovation Summit?
How can I access the webcast of G1 Therapeutics' fireside chat at the Oncology Innovation Summit?
What is the stock symbol for G1 Therapeutics?
